AstraZeneca Pharma India Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for AstraZeneca Pharma India.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 18.7% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease
Apr 04
Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Nov 10AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00
Jul 06Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Jun 16Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
Aug 02Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock
Feb 25Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Feb 04Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Jan 18
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years
Dec 31We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability
Dec 13Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching
Nov 25Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay
Nov 07What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Oct 20AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Sep 24If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today
Aug 28What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?
Aug 02Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Jul 12In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AstraZeneca Pharma India has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2023 | 11,970 | 1,393 | N/A | N/A | N/A |
| 9/30/2023 | 11,410 | 1,528 | 639 | 714 | N/A |
| 6/30/2023 | 10,661 | 1,330 | N/A | N/A | N/A |
| 3/31/2023 | 10,030 | 993 | 498 | 583 | N/A |
| 12/31/2022 | 9,502 | 1,100 | N/A | N/A | N/A |
| 9/30/2022 | 9,009 | 921 | 776 | 856 | N/A |
| 6/30/2022 | 8,625 | 715 | N/A | N/A | N/A |
| 3/31/2022 | 8,056 | 616 | 912 | 1,008 | N/A |
| 12/31/2021 | 7,839 | 609 | N/A | N/A | N/A |
| 9/30/2021 | 7,836 | 705 | 1,442 | 1,550 | N/A |
| 6/30/2021 | 7,954 | 849 | N/A | N/A | N/A |
| 3/31/2021 | 8,136 | 933 | 971 | 1,048 | N/A |
| 12/31/2020 | 7,982 | 756 | N/A | N/A | N/A |
| 9/30/2020 | 8,218 | 813 | 154 | 228 | N/A |
| 6/30/2020 | 8,208 | 693 | N/A | N/A | N/A |
| 3/31/2020 | 8,318 | 722 | 732 | 874 | N/A |
| 12/31/2019 | 8,272 | 725 | N/A | N/A | N/A |
| 9/30/2019 | 8,185 | 749 | 358 | 564 | N/A |
| 6/30/2019 | 7,714 | 696 | N/A | N/A | N/A |
| 3/31/2019 | 7,283 | 545 | 363 | 550 | N/A |
| 12/31/2018 | 6,887 | 478 | N/A | N/A | N/A |
| 9/30/2018 | 6,021 | 83 | N/A | N/A | N/A |
| 6/30/2018 | 6,050 | 265 | N/A | N/A | N/A |
| 3/31/2018 | 5,710 | 259 | 25 | 88 | N/A |
| 12/31/2017 | 5,319 | 175 | N/A | N/A | N/A |
| 9/30/2017 | 5,536 | 442 | N/A | N/A | N/A |
| 6/30/2017 | 5,275 | 176 | N/A | N/A | N/A |
| 3/31/2017 | 5,437 | 201 | N/A | 381 | N/A |
| 12/31/2016 | 5,866 | 279 | N/A | N/A | N/A |
| 9/30/2016 | 5,809 | 206 | N/A | N/A | N/A |
| 6/30/2016 | 5,711 | 131 | N/A | N/A | N/A |
| 3/31/2016 | 5,637 | 53 | N/A | 570 | N/A |
| 12/31/2015 | 5,529 | 428 | N/A | N/A | N/A |
| 9/30/2015 | 5,166 | 207 | N/A | N/A | N/A |
| 6/30/2015 | 4,753 | -5 | N/A | N/A | N/A |
| 3/31/2015 | 4,690 | -208 | N/A | -457 | N/A |
| 12/31/2014 | 4,624 | -615 | N/A | N/A | N/A |
| 9/30/2014 | 4,732 | -466 | N/A | N/A | N/A |
| 6/30/2014 | 4,742 | -199 | N/A | N/A | N/A |
| 3/31/2014 | 4,737 | -5 | N/A | -8 | N/A |
| 12/31/2013 | 4,545 | -165 | N/A | N/A | N/A |
| 9/30/2013 | 4,405 | -357 | N/A | N/A | N/A |
| 6/30/2013 | 4,241 | -796 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ASTRAZEN's forecast earnings growth is above the savings rate (6.7%).
Earnings vs Market: Insufficient data to determine if ASTRAZEN's earnings are forecast to grow faster than the Indian market
High Growth Earnings: Insufficient data to determine if ASTRAZEN's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if ASTRAZEN's revenue is forecast to grow faster than the Indian market.
High Growth Revenue: Insufficient data to determine if ASTRAZEN's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ASTRAZEN's Return on Equity is forecast to be high in 3 years time